Nancy E. Rosenstein
Nancy E. Rosenstein has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Bradley A. Perkins
6 shared publicationsTanja Popovic
Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Diseases , Atlanta, Georgia
4 shared publicationsDavid S. Stephens
Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Diseases , Atlanta, Georgia 5 Emory University School of Medicine , Atlanta, Georgia
3 shared publicationsBrian D. Plikaytis
Biostatistics and Information Management Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention , Atlanta
2 shared publicationsMarc Fischer
Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, and
2 shared publicationsSusanna Schmink
Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Diseases , Atlanta, Georgia
2 shared publications
Latest Publications
- Open Access
- 1 January 2005
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 191 (1) , 33-39
Neisseria meningitidisSerogroup W‐135 Carriage among US Travelers to the 2001 Hajj
In 2000, a large international outbreak of meningococcal disease caused by Neisseria meningitidis serogroup W-135 was identified among pilgrims retur
- 1 January 2005
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 191 (1) , 33-39
Open AccessNeisseria meningitidisSerogroup W‐135 Carriage among US Travelers to the 2001 Hajj
In 2000, a large international outbreak of meningococcal disease caused by Neisseria meningitidis serogroup W-135 was identified among pilgrims retur
- Open Access
- 1 October 2001
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 108 (4) , e60
Haemophilus influenzae Type b Disease Among Amish Children in Pennsylvania: Reasons for Persistent Disease
Objective. To identify reservoirs ofHaemophilus influenzae type b (Hib) pharyngeal carriage and assess barriers to vaccination among 2 Amish communities in Pennsylvania. Methods. We investigated recent cases, performed community surveys for Hib vaccination coverage and pharyngeal carriage, and administered a questionnaire assessing vaccination knowledge and attitudes to 298 members of 2 Amish communities (A and B) in Pennsylvania and, as a comparison group, 136 non-Amish family members who participated in state immunization clinics. From December 1999 to February 2000, 8 cases of invasive Hib disease occurred among children who were 5 years of age or younger in Pennsylvania. Six of the case-patients were from Amish communities. None of the children had been vaccinated. Results. Among children who were 5 years of age or younger, Hib vaccine coverage was low in the 2 Amish communities: A (9 [28%] of 32) and B (3 [7%] of 41) compared with the non-Amish group (19 [95%] of 20). Hib carriage prevalence was higher in both Amish communities than in the non-Amish group (A: 3%; B: 8%; non-Amish: 0%). More households in community B had 1 or more Hib carriers than in community A (8 [28%] of 29 vs 3 [9%] of 32). Among Amish parents who did not vaccinate their children, only 25% (13 of 51) identified either religious or philosophical objections as a factor; 51% (26 of 51) reported that vaccinating was not a priority compared with other activities of daily life. Seventy-three percent (36 of 49) would vaccinate their children if vaccination were offered locally. Conclusions. Undervaccinated communities in the United States still exist and allow circulation of Hib strains, resulting in disease among susceptible children. Identification of undervaccinated populations, such as the Amish, and targeted education and vaccination campaigns are essential to achieving elimination of Hib disease.
- 1 October 2001
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 108 (4) , e60
Open AccessHaemophilus influenzae Type b Disease Among Amish Children in Pennsylvania: Reasons for Persistent Disease
Objective. To identify reservoirs ofHaemophilus influenzae type b (Hib) pharyngeal carriage and assess barriers to vaccination among 2 Amish communities in Pennsylvania. Methods. We investigated recent cases, performed community surveys for Hib vaccination coverage and pharyngeal carriage, and administered a questionnaire assessing vaccination knowledge and attitudes to 298 members of 2 Amish communities (A and B) in Pennsylvania and, as a comparison group, 136 non-Amish family members who participated in state immunization clinics. From December 1999 to February 2000, 8 cases of invasive Hib disease occurred among children who were 5 years of age or younger in Pennsylvania. Six of the case-patients were from Amish communities. None of the children had been vaccinated. Results. Among children who were 5 years of age or younger, Hib vaccine coverage was low in the 2 Amish communities: A (9 [28%] of 32) and B (3 [7%] of 41) compared with the non-Amish group (19 [95%] of 20). Hib carriage prevalence was higher in both Amish communities than in the non-Amish group (A: 3%; B: 8%; non-Amish: 0%). More households in community B had 1 or more Hib carriers than in community A (8 [28%] of 29 vs 3 [9%] of 32). Among Amish parents who did not vaccinate their children, only 25% (13 of 51) identified either religious or philosophical objections as a factor; 51% (26 of 51) reported that vaccinating was not a priority compared with other activities of daily life. Seventy-three percent (36 of 49) would vaccinate their children if vaccination were offered locally. Conclusions. Undervaccinated communities in the United States still exist and allow circulation of Hib strains, resulting in disease among susceptible children. Identification of undervaccinated populations, such as the Amish, and targeted education and vaccination campaigns are essential to achieving elimination of Hib disease.
- Top Cited Papers
- 3 May 2001
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (18) , 1378-1388
Meningococcal Disease
Reports of illness resembling meningococcal disease date back to the 16th century. The description reported by Vieusseux in 1805 is generally thought to be the first definitive identification of the disease,1 and the causative organism, Neisseria meningitidis, was first isolated in 1887.2 Yet meningococcal disease remains a leading cause of bacterial meningitis and sepsis in the United States and a major cause of epidemics in sub-Saharan Africa. Short of abolishing tobacco use, which is thought to be responsible for almost one third of cases,3 routine vaccination of high-risk populations is likely to be the most effective public health strategy . . .
- 3 May 2001
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (18) , 1378-1388
Top Cited PapersMeningococcal Disease
Reports of illness resembling meningococcal disease date back to the 16th century. The description reported by Vieusseux in 1805 is generally thought to be the first definitive identification of the disease,1 and the causative organism, Neisseria meningitidis, was first isolated in 1887.2 Yet meningococcal disease remains a leading cause of bacterial meningitis and sepsis in the United States and a major cause of epidemics in sub-Saharan Africa. Short of abolishing tobacco use, which is thought to be responsible for almost one third of cases,3 routine vaccination of high-risk populations is likely to be the most effective public health strategy . . .
- 1 March 2001
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 15 (1) , 155-169
Meningococcal Vaccines
- 1 March 2001
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 15 (1) , 155-169
Meningococcal Vaccines
- Open Access
- 1 March 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (5) , 708-714
Risk Factors for Severe Pulmonary and Disseminated Coccidioidomycosis: Kern County, California, 1995-1996
Surveillance for coccidioidomycosis (CM) and a case-control study for risk factors among adults were conducted in Kern County, California. From Janua
- 1 March 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (5) , 708-714
Open AccessRisk Factors for Severe Pulmonary and Disseminated Coccidioidomycosis: Kern County, California, 1995-1996
Surveillance for coccidioidomycosis (CM) and a case-control study for risk factors among adults were conducted in Kern County, California. From Janua
- 1 April 2000
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 47 (2) , 337-352
UPDATE ON HAEMOPHILUS INFLUENZAE SEROTYPE b AND MENINGOCOCCAL VACCINES
- 1 April 2000
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 47 (2) , 337-352
UPDATE ON HAEMOPHILUS INFLUENZAE SEROTYPE b AND MENINGOCOCCAL VACCINES
- Open Access
- 1 January 2000
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 30 (1) , 212-213
Antimicrobial Resistance of Neisseria meningitidis in the United States, 1997
Chemoprophylaxis for close contacts of patients with sporadic cases of meningococcal disease is effective in preventing secondary cases of disease [3]. Our fail
- 1 January 2000
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 30 (1) , 212-213
Open AccessAntimicrobial Resistance of Neisseria meningitidis in the United States, 1997
Chemoprophylaxis for close contacts of patients with sporadic cases of meningococcal disease is effective in preventing secondary cases of disease [3]. Our fail
- Open Access
- 1 December 1999
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 180 (6) , 1894-1901
The Changing Epidemiology of Meningococcal Disease in the United States, 1992–1996
New meningococcal vaccines are undergoing clinical trials, and changes in the epidemiologic features of meningococcal disease will affect their use.
- 1 December 1999
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 180 (6) , 1894-1901
Open AccessThe Changing Epidemiology of Meningococcal Disease in the United States, 1992–1996
New meningococcal vaccines are undergoing clinical trials, and changes in the epidemiologic features of meningococcal disease will affect their use.
- Open Access
- 11 February 1998
- Published by American Medical Association (AMA) in JAMA
- Vol. 279 (6) , 435-439
Efficacy of Meningococcal Vaccine and Barriers to Vaccination
NEISSERIA MENINGITIDIS is a leading cause of bacterial meningitis in the United States, causing an estimated 2600 cases of invasive disease annually, with a mortality rate between 10% and 15%.1 In the United States, N meningitidis serogroup C accounts for 30% to 40% of invasive disease and is the most common cause of outbreaks.2 Outbreaks of serogroup C meningococcal disease (SCMD) have been rare in the United States since World War II; however, since 1991, the number of serogroup C outbreaks has increased.2 The quadrivalent meningococcal polysaccharide vaccine, which contains the purified polysaccharide capsules of serogroups A, C, W-135, and Y, has been recommended for the control of SCMD outbreaks.3
- 11 February 1998
- Published by American Medical Association (AMA) in JAMA
- Vol. 279 (6) , 435-439
Open AccessEfficacy of Meningococcal Vaccine and Barriers to Vaccination
NEISSERIA MENINGITIDIS is a leading cause of bacterial meningitis in the United States, causing an estimated 2600 cases of invasive disease annually, with a mortality rate between 10% and 15%.1 In the United States, N meningitidis serogroup C accounts for 30% to 40% of invasive disease and is the most common cause of outbreaks.2 Outbreaks of serogroup C meningococcal disease (SCMD) have been rare in the United States since World War II; however, since 1991, the number of serogroup C outbreaks has increased.2 The quadrivalent meningococcal polysaccharide vaccine, which contains the purified polysaccharide capsules of serogroups A, C, W-135, and Y, has been recommended for the control of SCMD outbreaks.3
- 1 December 1997
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 90 (6) , 901-906
Opportunities for Prevention of Perinatal Group B Streptococcal Disease: A Multistate Surveillance Analysis
To evaluate the potential impact of ACOG and Centers for Disease Control and Prevention (CDC) consensus strategies for the prevention of perinatal group B streptococcal disease. We evaluated cases of early-onset group B streptococcal disease identified by active surveillance during 1995, in four areas in North America with an aggregate 186,000 births per year. We reviewed the hospital records of mothers and infants and any prenatal records available on site. Cases were determined to be preventable based on whether group B streptococcal screening could have been performed prenatally, sensitivity of screening, presence of obstetric complications, and opportunity to administer antibiotics. We reviewed records for 245 of 246 infants with early-onset group B streptococcal disease in the surveillance areas. Most of the 53 case-mothers who delivered preterm and 192 who delivered full-term had had at least one prenatal visit (83% and 99%, respectively). Few case-mothers had prenatal group B streptococcal screening cultures, although compliance was high for other prenatal screening tests. Fifty-four percent of case-mothers had a recognized obstetric risk factor for group B streptococcal disease: labor or rupture of membranes at less than 37 weeks, rupture of membranes for 18 hours on longer, or temperature 38C or greater. The estimated preventable portion of early-onset group B streptococcal cases was 78% for the screening-based approach (range 74% to 82% by area), compared with 41% for the risk-based approach (range 39% to 53% by area). Comprehensive implementation of either of the recommended prevention strategies could potentially prevent a substantial proportion of early-onset group B streptococcal disease.
- 1 December 1997
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 90 (6) , 901-906
Opportunities for Prevention of Perinatal Group B Streptococcal Disease: A Multistate Surveillance Analysis
To evaluate the potential impact of ACOG and Centers for Disease Control and Prevention (CDC) consensus strategies for the prevention of perinatal group B streptococcal disease. We evaluated cases of early-onset group B streptococcal disease identified by active surveillance during 1995, in four areas in North America with an aggregate 186,000 births per year. We reviewed the hospital records of mothers and infants and any prenatal records available on site. Cases were determined to be preventable based on whether group B streptococcal screening could have been performed prenatally, sensitivity of screening, presence of obstetric complications, and opportunity to administer antibiotics. We reviewed records for 245 of 246 infants with early-onset group B streptococcal disease in the surveillance areas. Most of the 53 case-mothers who delivered preterm and 192 who delivered full-term had had at least one prenatal visit (83% and 99%, respectively). Few case-mothers had prenatal group B streptococcal screening cultures, although compliance was high for other prenatal screening tests. Fifty-four percent of case-mothers had a recognized obstetric risk factor for group B streptococcal disease: labor or rupture of membranes at less than 37 weeks, rupture of membranes for 18 hours on longer, or temperature 38C or greater. The estimated preventable portion of early-onset group B streptococcal cases was 78% for the screening-based approach (range 74% to 82% by area), compared with 41% for the risk-based approach (range 39% to 53% by area). Comprehensive implementation of either of the recommended prevention strategies could potentially prevent a substantial proportion of early-onset group B streptococcal disease.